Provided by Tiger Trade Technology Pte. Ltd.

Day One Biopharmaceuticals Inc.

21.41
+0.01000.05%
Post-market: 21.420.0100+0.05%16:43 EDT
Volume:2.37M
Turnover:50.69M
Market Cap:2.21B
PE:-20.59
High:21.44
Open:21.43
Low:21.40
Close:21.40
52wk High:21.46
52wk Low:5.64
Shares:103.30M
Float Shares:78.77M
Volume Ratio:0.71
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0400
EPS(LYR):-1.0400
ROE:-22.74%
ROA:-14.64%
PB:5.01
PE(LYR):-20.59

Loading ...

BRIEF-Servier And Day One Biopharmaceuticals Announce Acquisition To Expand Servier’S Rare Oncology Portfolio

Reuters
·
Mar 06

Servier to buy Day One Biopharmaceuticals for $2.5 billion in cash

Reuters
·
Mar 06

Servier and Day One Biopharmaceuticals Announce Acquisition to Expand Servier’s Rare Oncology Portfolio

THOMSON REUTERS
·
Mar 06

Day One Biopharmaceuticals Inc - Servier Expects to Fund Deal Through Existing Cash and Investments

THOMSON REUTERS
·
Mar 06

Day One Biopharmaceuticals Inc - Servier to Buy Day One for $21.50 per Share, Total Equity Value $2.5 Bln

THOMSON REUTERS
·
Mar 06

Press Release: Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

Dow Jones
·
Mar 06

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM

Reuters
·
Mar 06

Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Keros Therapeutics (KROS) and Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Mar 05

Day One Biopharmaceuticals up 11% after rumor highlighted in Betaville blog

TIPRANKS
·
Mar 05

Day One Biopharmaceuticals: Ojemda Uptake, Strong 2026 Guidance, and Underappreciated Emi‑Le Catalyst Support Buy Rating

TIPRANKS
·
Mar 03

BRIEF-EMA Recommends Granting Conditional Marketing Authorisation In EU For Ojemda

Reuters
·
Feb 27

Stock Track | Day One Biopharmaceuticals Plummets 7.03% Intraday After H.C. Wainwright Cuts Price Target

Stock Track
·
Feb 25

Stock Track | Day One Biopharmaceuticals Plunges 5.99% in Pre-market After H.C. Wainwright Cuts Price Target

Stock Track
·
Feb 25

Wedbush Raises Price Target on Day One Biopharmaceuticals to $30 From $29, Keeps Outperform Rating

MT Newswires Live
·
Feb 25

Piper Sandler Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
Feb 25

Day One price target lowered to $22 from $25 at H.C. Wainwright

TIPRANKS
·
Feb 25

Day One Biopharm Is Maintained at Buy by Needham

Dow Jones
·
Feb 25

Stock Track | Day One Biopharmaceuticals Plunges 6.74% After Q4 Earnings Miss Analyst Expectations

Stock Track
·
Feb 25

Day One Biopharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 25

Day One Biopharmaceutical Q4 Sales $53.700M Beat $47.605M Estimate

Benzinga
·
Feb 25